Skip to content
Mitochondrial Peptide

MOTS-c

A 16-amino acid peptide encoded within mitochondrial DNA - one of the first mitochondria-derived peptides ever discovered. Regulates glucose metabolism, activates AMPK, and mimics the metabolic effects of exercise at the cellular level. A defining longevity compound of 2026 research.

metabolic-healthlongevityenergyperformance
Tier B— Generally safe — moderate evidence
Evidence gradeC — Animal studies / Case reports
BH

Editorially reviewed by

BiohackingHub Research Team

Editorial Team · Last updated: October 3, 2026

What Makes MOTS-c Unique

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) was discovered in 2015 by researchers at USC. It is one of the first peptides identified as being encoded within mitochondrial DNA -- a discovery that changed our understanding of how mitochondria communicate with the rest of the cell.

Mechanism of Action

  • AMPK activation -- MOTS-c activates AMPK through a pathway independent of the AMP/ATP ratio, enabling metabolic adaptation even when cellular energy is not depleted
  • Glucose regulation -- translocates to the nucleus under metabolic stress, regulating genes involved in glucose homeostasis and insulin sensitivity
  • Exercise mimetic -- animal studies show MOTS-c injection produces metabolic adaptations similar to endurance exercise: increased fatty acid oxidation and improved mitochondrial efficiency
  • Anti-inflammatory -- modulates inflammatory cytokine production, reducing chronic low-grade inflammation

The 2026 Research Landscape

MOTS-c is receiving significant research attention for metabolic syndrome, type 2 diabetes, and sarcopenia. Reviews of the field report that plasma MOTS-c declines with age.

Three findings since the original 2015 paper are worth knowing:

  • It works at every age in mice. Treatment improved physical performance in mice aged 2, 12 and 22 months, and intermittent treatment begun late in life increased physical capacity and healthspan.
  • A human gene variant points the same way. An Asian-specific mitochondrial DNA variant produces a less active MOTS-c (K14Q). Across three cohorts totalling 27,527 people, men carrying it had more type 2 diabetes — and in one cohort only those in the lowest third of physical activity.
  • It improves mitochondrial efficiency, not quantity. 2026 work in mice found better muscle mitochondrial bioenergetics through PGC-1α and AMPK without a change in respiratory protein content.

What Has Not Been Shown

No published trial has administered MOTS-c to humans. The dosing above is a community convention extrapolated from animal work, not a trial-derived dose, and there are no human pharmacokinetic or safety data. In people, the intervention shown to raise MOTS-c is acute high-intensity exercise. Evidence grade C here reflects the human genetic and observational data alongside the animal work; for supplementation specifically, the evidence is preclinical.

MOTS-c is an AMPK activator, a class prohibited in tested sport.

Related Research

Stacking Interactions

How MOTS-c interacts with other compounds

+
NMNSynergisticweak evidence

Advanced metabolic stack. MOTS-c cycles 4-8 weeks; NMN daily. Use concurrently during active MOTS-c cycles.

+
BerberineSynergisticweak evidence

Both activate AMPK through different mechanisms. Additive metabolic benefits. Monitor for hypoglycaemia.

=
HumaninNeutralanecdotal evidence

The other well-characterised mitochondrial-derived peptide, encoded in the neighbouring 16S rRNA gene. Humanin is cytoprotective, MOTS-c metabolic. The combination has no study in any species, and humanin has no human dose.

=
Coenzyme Q10Neutralweak evidence

The mitochondrial layer with human outcome trials. In the Mito-Peptide Advanced protocol CoQ10 runs from week 0 and MOTS-c is the optional experimental layer added later.

Protocols using MOTS-c

Evidence-graded stacks that include this compound

Safety Profile — Tier B

Generally safe — moderate evidence

Contraindications

  • ●Pregnancy - insufficient safety data
  • ●Active cancer - research ongoing

Side Effects

  • ●Injection site reactions (subcutaneous)
  • ●Mild fatigue in early days (metabolic adaptation)
  • ●Long-term safety profile not yet established

Drug Interactions

Metformin - potential additive AMPK activation; monitor glucoseInsulin - additive glucose-lowering effect